Wyeth LLC v. AstraZeneca Pharmaceuticals LP, No. 24-2325 (Fed. Cir. July 9, 2026)

Editorial Summary

AI-assisted editorial summary; not attorney-reviewed. Verify against the opinion itself before relying on any characterization of the holding.

Wyeth appealed from the District of Delaware's grant of judgment as a matter of law that asserted claims 1, 3, and 9 of U.S. Patent 10,603,314 and claim 1 of U.S. Patent 10,596,162 are invalid for lack of enablement. The claims were directed to dosage forms, yet the specifications disclosed only a broad range of doses — some of which were shown to be toxic — and no actual dosages for any compound within the scope of the claims, leaving practitioners to engage in undue experimentation. The Federal Circuit acknowledged that method-of-treatment claims may ordinarily recite dose ranges without clinical data, but held that these patents' failure to enable the claimed dosage forms was fatal. The grant of JMOL of invalidity was affirmed.